OXERVATE Market Summary

Key Factors Driving OXERVATE Growth

1. First-in-class therapy for a rare disease (monopoly positioning)

• OXERVATE is the first and only FDA-approved treatment for neurotrophic keratitis (NK)
• NK is a rare, progressive disease with no prior pharmacologic therapies, affecting <65,000 patients in the US.

2. Novel mechanism targeting root cause (NGF-based regeneration)

• Recombinant human nerve growth factor (NGF) restores corneal innervation and integrity
• First-ever topical biologic in ophthalmology targeting disease pathophysiology

3. Strong clinical efficacy and durability

• Clinical trials showed:

o ~72% complete corneal healing at 8 weeks vs ~33% placebo

o ~80% of responders remained healed at 1 year

4. Orphan drug advantages and regulatory support

• Granted:

o Orphan Drug Designation

o Fast Track and Breakthrough Therapy Designation

Growth implication:

• Market exclusivity and limited competition
• Faster development timelines and reimbursement support

5. Premium pricing in rare disease segment

• OXERVATE is widely recognized as a high-cost therapy (tens of thousands USD per 8-week course) (reported across payer and clinical literature)

6. Lifecycle expansion into broader ocular diseases

• Ongoing development in:

o Sjögren’s-related dry eye disease (Phase III)

• NGF biology is being explored in:

o Dry eye disease

o Corneal nerve damage disorders

OXERVATE Recent Developments

• In October 2025, Dompé announced FDA selection for the Commissioner's National Priority Voucher (CNPV) program to expedite an intranasal cenegermin-bkbj formulation for non-arteritic anterior ischemic optic neuropathy (NAION), building on Oxervate's NGF platform.

“OXERVATE Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OXERVATE for approved indication like Keratitis; as well as potential indication like Dry eyes, Glaucoma, Ischaemic optic neuropathy, and Retinitis pigmentosa in the 7MM. A detailed picture of OXERVATE’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the OXERVATE for approved and potential indications. The OXERVATE market report provides insights about OXERVATE’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OXERVATE performance, future market assessments inclusive of the OXERVATE market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OXERVATE sales forecasts, along with factors driving its market.

OXERVATE Drug Summary

OXERVATE is a recombinant human nerve growth factor (rhNGF) ophthalmic solution developed by Dompé for the treatment of neurotrophic keratitis, a rare and progressive eye disorder characterized by impaired corneal innervation and poor healing. Administered as topical eye drops six times daily over an eight-week course, OXERVATE works by mimicking endogenous nerve growth factor to stimulate corneal nerve regeneration, enhance epithelial cell proliferation, and promote corneal healing. Its mechanism addresses the underlying cause of the disease rather than just managing symptoms, distinguishing it from conventional supportive therapies such as artificial tears. Clinical trials have demonstrated significantly higher rates of complete corneal healing compared to placebo, leading to its regulatory approval in multiple regions including the US and Europe. OXERVATE is considered a first-in-class regenerative therapy in ophthalmology, offering a disease-modifying treatment option for patients with moderate to severe neurotrophic keratitis. The report provides OXERVATE’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the OXERVATE Market Report

The report provides insights into:

• A comprehensive product overview including the OXERVATE MoA, description, dosage and administration, research and development activities in approved indications like Keratitis; as well as potential indication like Dry eyes, Glaucoma, Ischaemic optic neuropathy, and Retinitis pigmentosa.
• Elaborated details on OXERVATE regulatory milestones and other development activities have been provided in OXERVATE market report.
• The report also highlights OXERVATE‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The OXERVATE market report also covers the patents information, generic entry and impact on cost cut.
• The OXERVATE market report contains current and forecasted OXERVATE sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OXERVATE market report also features the SWOT analysis with analyst views for OXERVATE in approved and potential indications.

Methodology

The OXERVATE market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OXERVATE Analytical Perspective by DelveInsight

• In-depth OXERVATE Market Assessment

This OXERVATE sales market forecast report provides a detailed market assessment of OXERVATE for approved indication like Keratitis; as well as potential indication like Dry eyes, Glaucoma, Ischaemic optic neuropathy, and Retinitis pigmentosa in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OXERVATE sales data uptil 2034.

• OXERVATE Clinical Assessment

The OXERVATE market report provides the clinical trials information of OXERVATE for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OXERVATE Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OXERVATE Market Potential & Revenue Forecast

• Projected market size for the OXERVATE and its key indications
• Estimated OXERVATE sales potential (OXERVATE peak sales forecasts)
• OXERVATE Pricing strategies and reimbursement landscape

OXERVATE Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OXERVATE Market positioning compared to existing treatments
• OXERVATE Strengths & weaknesses relative to competitors

OXERVATE Regulatory & Commercial Milestones

• OXERVATE Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

OXERVATE Clinical Differentiation

• OXERVATE Efficacy & safety advantages over existing drugs
• OXERVATE Unique selling points

OXERVATE Market Report Highlights

• In the coming years, the OXERVATE market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The OXERVATE companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OXERVATE’s dominance.
• Other emerging products for Keratitis; as well as potential indication like Dry eyes, Glaucoma, Ischaemic optic neuropathy, and Retinitis pigmentosa are expected to give tough market competition to OXERVATE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OXERVATE in approved and potential indications.
• Analyse OXERVATE cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OXERVATE sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OXERVATE in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of OXERVATE? How strong is OXERVATE’s clinical and commercial performance?
• What is OXERVATE’s clinical trial status in each individual indications such as Keratitis; as well as potential indication like Dry eyes, Glaucoma, Ischaemic optic neuropathy, and Retinitis pigmentosa and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OXERVATE Manufacturers?
• What are the key designations that have been granted to OXERVATE for approved and potential indications? How are they going to impact OXERVATE’s penetration in various geographies?
• What is the current and forecasted OXERVATE market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of OXERVATE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to OXERVATE for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is OXERVATE? What is the duration of therapy and what are the geographical variations in cost per patient?